Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBITDA Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBITDA Margin for 15 consecutive years, with 0.32% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 207.0% to 0.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.85% through Dec 2025, down 543.0% year-over-year, with the annual reading at 9.85% for FY2025, 543.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 0.32% at Gyre Therapeutics, down from 22.66% in the prior quarter.
  • The five-year high for EBITDA Margin was 414.72% in Q4 2021, with the low at 1851.51% in Q1 2022.
  • Average EBITDA Margin over 5 years is 333.13%, with a median of 9.21% recorded in 2025.
  • The sharpest move saw EBITDA Margin plummeted -149855bps in 2021, then skyrocketed 187824bps in 2023.
  • Over 5 years, EBITDA Margin stood at 414.72% in 2021, then plummeted by -105bps to 22.13% in 2022, then crashed by -1425bps to 337.53% in 2023, then surged by 101bps to 2.39% in 2024, then plummeted by -87bps to 0.32% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 0.32%, 22.66%, and 8.11% for Q4 2025, Q3 2025, and Q2 2025 respectively.